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Abstract 
The initial detection and identification of suspicious lesions and the precise delineation of tumour margins are 
essential for successful tumour resection, with progression-free survival linked to rates of complete resection. 
However, post-surgical positive margin rates remain high for many cancers and despite numerous advances in 
intraoperative imaging and diagnostic technologies, there exists no single modality that can adequately perform 
both tumoural detection and delineation. Here, we demonstrate a multimodal computer vision-based diagnostic 
system capable of both the gross detection and identification of suspicious lesions and the precise delineation 
of disease margins. We first show that through visual tracking of a spectroscopic probe, we enable real-time 
tumour margin delineation both for ex vivo human tumour biopsies and for an in vivo tumour xenograft mouse 
model. We then demonstrate that the combination of Raman spectroscopic diagnoses with protoporphyrin IX 
(PPIX) fluorescence imaging enables fluorescence-guided Raman spectroscopic margin delineation. Our fluo-
rescence-guided Raman spectroscopic system achieves superior margin delineation accuracy to fluorescence 
imaging alone, demonstrating the potential for our system to achieve improved clinical outcomes for tumour 
resection surgeries. 
 
Introduction 
Accurate delineation of tumour margins is essential 
for improving cancer survival rates as incomplete tu-
mour resection has been shown to significantly reduce 
long-term survival rates for a range of cancers1–3. 
However, the need for maximal resection needs to be 
balanced with the goal of healthy tissue preservation 
in order to minimise patient discomfort and functional 
impairment. Many groups have thus been researching 
advanced imaging and spectroscopic techniques for 
improved tumour visualisation and margin delinea-
tion4–7. Fluorescence-guided surgery (FGS) has, for 
example, been employed with great success for the 
visualisation of high-grade gliomas using fluoro-
phores, enabling improved rates of complete resection 
and progression-free survival relative to conventional 
microsurgery8–10. This technique has however been 
somewhat limited by difficulties in the quantification 
of fluorescence levels due to varying tissue optical 
properties and low sensitivities for early-stage can-
cers11–13. 
As an alternative, many groups have investigated the 
application of pointwise optical techniques such as 
fluorescence spectroscopy7,14,15, reflectance spectros-
copy16–18, Raman spectroscopy4,19,20, optical coher-
ence tomography21–23, and confocal endomicros-
copy24,25 for cancer detection and diagnosis. These 
techniques probe the optical or endogenous biomolec-
ular properties of the tissue itself, revealing differ-
ences between healthy and diseased tissue that can be 
used to provide accurate diagnosis. For example, flu-
orescence spectroscopy has been applied to skin can-
cer diagnosis26,27 and as a quantitative adjunct to fluo-
rescence imaging of gliomas during brain surgery11,15. 
Reflectance spectroscopy has been used for the detec-
tion of cervical precancers in vivo16 and in combina-
tion with fluorescence spectroscopy for the in vivo de-
tection of breast, brain, and ovarian cancers17,18,28. 
Similarly, Raman spectroscopy has enabled highly 
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accurate in vivo diagnosis of a range of cancers includ-
ing breast, skin, colon, gastric, and oesophageal can-
cers, exploiting the interaction of light with molecular 
bonds to identify the chemical species present in a 
sample4,19,29–31. 
Though each of these spectroscopic modalities has 
shown promise in the accurate diagnosis of cancerous 
tissues, clinical utilisation is hindered by the lack of 
widefield imaging. As spectroscopic techniques, these 
methods typically involve the collection of point spec-
tra via a handheld fibreoptic probe, providing diagnos-
tic information at discrete locations, rather than a di-
agnostic image for a large area, as is the case with flu-
orescence imaging18. As such, although they can pro-
vide highly accurate diagnoses of a given point, tu-
mour margin delineation is unrealistic unless clini-
cians can visualise and record diagnoses for multiple 
points simultaneously32. Further, particularly in the 
case of Raman spectroscopy, pixel-by-pixel measure-
ment of a surgical field-of-view (FOV) is infeasible 
owing to infrequency of Raman scattering events, 
which necessitates relatively long acquisition times to 
generate sufficient signal33. Importantly, however, 
these diagnostic modalities offer different, yet com-
plementary information. While widefield imaging 
provides crucial macroscopic morphological infor-
mation, it lacks the microscopic biochemical infor-
mation offered by many pointwise optical techniques. 
Therefore, the development of a system that effec-
tively combines spatially co-registered spectroscopic 
diagnostic information with widefield imaging could 
vastly improve the clinical utility of handheld spectro-
scopic probes for cancer diagnostics.  
Here we present a new approach for the acquisition of 
spatial spectroscopic diagnostic information via com-
puter vision tracking of a handheld spectroscopic 
probe. Our system enables simultaneous recording of 
both the position and orientation (pose) of the spectro-
scopic probe as well as the diagnostic spectroscopic 
information for each measurement acquisition. To-
gether, the data is overlaid onto imaging of the surgi-
cal FOV to provide a near real-time augmented reality 
(AR) display of the FOV. We demonstrate our system 
is capable of near real-time operation for accurate le-
sion mapping both ex vivo and in vivo under white 
light image guidance, providing comprehensive clini-
cal control over diagnostic parameters to enable sys-
tem tuning to varied clinical contexts. We further 
show that our system can be extended to include fluo-
rescence image guidance, resulting in improved mar-
gin delineation of fluorescent optical tissue phantoms 
than fluorescence imaging alone. Our fluorescence-
guided Raman spectroscopic system thus helps to 
bridge the gap between point-based spectroscopic di-
agnoses and imaging information, overcoming the 
trade-off between diagnostic accuracy and FOV that 
has to date limited spectroscopic diagnostic systems. 
 
Results 
Fluorescence-Guided Raman Spectroscopic Sys-
tem Development 
Our fluorescence-guided Raman spectroscopic system 
combines widefield imaging with Raman spectro-
scopic information, and consists of a camera for white 
light/fluorescence imaging, a handheld fibreoptic 
probe, a laser and spectrograph for Raman spectros-
copy, an excitation light source, collection filter optics 
for fluorescence imaging, and a computer with inte-
grated software for clinical control (Figure 1). Clinical 
application of our system necessitates a probe-track-
ing algorithm that is robust under varied settings in-
cluding different lighting conditions, imaging devices, 
and spectroscopic probes. We therefore aimed to de-
velop a system that could be readily translated across 
different environments with minimal technical re-
quirements while maintaining real-time capabilities. 
To achieve this, we implemented a marker-based vis-
ual tracking algorithm that combines visual detection 
and tracking of coloured markers with a priori 
knowledge of probe geometry to determine the posi-
tion and orientation (pose) of a probe for spatial diag-
nostics (Figure 2). 
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Figure 1 | Fluorescence-Guided Raman Spectroscopic System. Schematic of the fluorescence-guided Raman spectro-
scopic system comprising a camera for white light/fluorescence imaging, a handheld fibreoptic probe, a laser and spec-
trograph for Raman spectroscopy, an excitation light source, collection filter optics for fluorescence imaging, and a com-
puter with integrated software for clinical control. 
 
In the probe-tracking schema we developed, initial 
manual identification of the coloured, fiducial probe 
markers in the FOV enables HSV (Hue, Saturation, 
Value)-based image segmentation (Supplementary 
Figure 1), which is then combined with a priori 
knowledge of the probe and marker geometry for rati-
ometric calculation of the pose of both the spectro-
scopic probe and the probe tip (point of measurement 
acquisition) (Figure 2, I-II). The HSV colour space is 
used here as it has been shown to be superior to the 
RGB colour space for surgical tool tracking due to its 
decoupling of the chromaticity and luminance compo-
nents34,35. Continuous acquisition (Figure 2, III) over-
lays the tracked location of the probe tip onto the clin-
ical imaging video and records Raman spectral signal 
in real-time. Upon user identification of a region of 
interest, the system (Figure 2, IV) records both the lo-
cation of the probe tip and a Raman spectral signal for 
diagnosis. This Raman spectral signal is then diag-
nosed in real-time through application of a previously 
developed diagnostic model (e.g. partial least squares-
discriminant analysis (PLS-DA)) (Figure 2, V) and the 
diagnoses displayed at the probe tip coordinates are 
overlayed onto the clinical imaging video. Positive di-
agnoses are then connected to form a boundary that 
outlines the lesion margin. Importantly, the algorithm 
operates independently on each input video frame, ac-
cessing any previously stored diagnostic measure-
ments to update margin delineation at each step, to en-
sure robust performance following temporary occlu-
sion of the spectroscopic probe (Supplementary Fig-
ure 2).
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Figure 2 | Fluorescence-Guided Raman Spectroscopic System Software Process Flow. Schematic of fluorescence-guided 
Raman spectroscopic system software flow; (I) Video is initialised with diagnostic probe and interrogation area within 
FOV, (II) User interaction enables coloured-marker-based image segmentation which is combined with probe kinematic 
information for real-time probe tracking, (III) Once selected, the software begins near real-time data acquisition, contin-
ually tracking the diagnostic probe and recording spectral diagnostic information until the user starts a diagnostic acqui-
sition, (IV) When the user starts a diagnostic acquisition, the coordinates of the probe are recorded and a detailed spectral 
signal acquired. This spectral signal is then diagnosed as either positive (V, i) or negative (V, ii) using a pre-developed 
spectroscopic diagnostic model. The diagnosis is then overlaid onto the imaging information at the coordinates where 
the measurement was acquired. Positive diagnosis coordinates are connected to form a boundary that delineates the 
tumour margin.
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White Light-Guided Spectroscopic Margin Deline-
ation Ex Vivo  
For ex vivo and in vivo applications, we implemented 
our spectroscopic margin delineation algorithm (Fig-
ure 2) within a clinician-facing graphical user inter-
face (GUI) that provides functionality for system cal-
ibration, diagnostic spectroscopic model develop-
ment, and margin delineation. The fluorescence-
guided Raman spectroscopic system control software 
provides both a raw video input display and an aug-
mented reality (AR) display of the surgical field of 
view, with spatially co-registered spectroscopic diag-
nostic information overlaid onto the raw video input.  
Here, we examined the tissue discrimination capacity 
of our fluorescence-guided Raman spectroscopic sys-
tem ex vivo using a combination of human squamous 
cell carcinoma (SCC) biopsy samples (n = 10 tissues) 
and human normal (muscle/non-cancerous and fatty) 
tissue samples obtained from abdominoplasty proce-
dures (n = 4 tissues). Raman spectra were acquired us-
ing our fluorescence-guided Raman spectroscopic 
system for cancerous tissue (n = 201 spectra), normal 
(muscle/non-cancerous) tissue (n = 64 spectra), and 
normal (fatty) tissue (n = 89 spectra) with a 1 second 
acquisition time. Together, these spectra were used to 
develop a PLS-DA model discriminating between 
cancerous, normal (muscle/non-cancerous), and nor-
mal (fatty) tissue with cross-validated accuracies of 
92.0%, 90.6%, and 95.7%, respectively (Supplemen-
tary Figure 3). Using this model, we were able to ef-
fectively delineate a region of cancerous tissue from 
surrounding normal (muscle/non-cancerous) and nor-
mal (fatty) tissue for a human squamous cell carci-
noma biopsy sample, confirmed histologically using 
adjacent haematoxylin and eosin (H&E) stained sec-
tions (Figure 3, Supplementary Video 1). The system 
displays real-time spectroscopic information and au-
tomated PLS-DA diagnosis for each acquisition, 
providing an AR display of the specimen where the 
locations of negative (non-cancerous) acquisitions are 
displayed as green squares (with numbers indicating 
order of acquisition) and the locations of positive 
(cancerous) acquisitions are displayed as red squares 
(Figure 3a,d). The locations of positive diagnoses are 
then used to automatically delineate a predicted can-
cerous region, updated in real-time as subsequent di-
agnostic acquisitions are performed.  
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Figure 3 | White Light-Guided Spectroscopic Margin Delineation Ex Vivo. (a) Screenshot of the fluorescence-guided 
Raman spectroscopic system GUI during spectroscopic margin delineation of a human SCC biopsy specimen. This GUI 
provides the clinical interface between the surgeon and the system, providing a series of diagnostic controls as well as 
diagnostic spectral, statistical, and spatial information. (b) Adjacent hematoxylin and eosin (H&E) stained section of SCC 
biopsy specimen (scale bar = 2 mm). (c) White light image of the bulk SCC biopsy specimen. (d) White light image of the 
bulk tumour biopsy specimen with overlaid Raman spectral measurements and tumour margin delineation (red) where 
green squares indicate locations negative (non-cancerous) measurements, red squares (obscured under tumour margin 
delineation) indicate locations positive (cancerous) measurements, and the numbers inside each square indicate order 
of acquisition. 
 
To further examine the potential for clinical operation 
of our system, we investigated the probe tracking and 
margin delineation accuracies as well as its computa-
tional performance (Supplementary Figure 4). Probe 
tracking accuracy, assessed in a mock ex vivo setting 
using fresh chicken muscle tissue, demonstrated a 
mean probe tip tracking error of 1.07 ± 0.50 mm for a 
180-frame video sequence of input size 640 x 480 pix-
els with a working distance of 20 cm, in line with ex-
isting research and commercial optical tracking sys-
tems, which have reported errors of between 0.5 - 4 
mm36–39 (Supplementary Figure 4a,c,d). Similarly, 
computational performance, measured during a mock 
spatial diagnostic procedure, yielded a processing 
time of 0.21 ± 0.03 seconds during initial probe track-
ing (0.1 second Raman spectral integration time) 
(Supplementary Figure 4b, i). Acquisition of the first 
diagnostic acquisition required 3.91 ± 0.11 seconds (1 
second Raman spectral integration time) (Supplemen-
tary Figure 4b, ii), with subsequent diagnostic acqui-
sitions requiring just 1.90 ± 0.13 seconds (1 second 
Raman spectral integration time) (Supplementary Fig-
ure 4b, iii) due to MATLAB’s just-in-time compila-
tion40. Subsequent probe tracking processing time sta-
bilised at 0.49 ± 0.09 seconds (0.1 second Raman 
spectral integration time) (Supplementary Figure 4b, 
iv). 
While probe tracking here is performed in near real 
time (~2-5 frames per second (fps)) using a laptop, im-
plementation on a more powerful computer together 
with code parallelisation would likely enable real time 
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performance. Indeed, real time (> 30 fps) surgical tool 
tracking has been demonstrated using similar visual 
coloured marker-based tracking approaches (~55 
fps)41 and more recently with fully convolutional neu-
ral network deep learning strategies (~30 fps)42. The 
most significant impact on computational perfor-
mance in our system is the integration time required 
for the acquisition of Raman spectral data (0.1 seconds 
for continuous acquisitions during probe movement 
and 1 second for diagnostic acquisitions). In each 
case, the integration times applied could likely be sig-
nificantly reduced (by a factor of up to 10x) as in vivo 
Raman spectroscopic diagnostics has been achieved 
using integration times as low as 0.1 seconds19,43,44.  
To support clinical operation, we implemented several 
features designed to enable users to tailor spatial spec-
troscopic diagnostics to a particular patient or lesion 
(Supplementary Figure 5, Supplementary Video 2). 
These features, comprising adjustable safety margins, 
automatic suggested measurement locations, adjusta-
ble diagnostic thresholds, and video stabilisation, 
were demonstrated using an ex vivo fresh chicken tis-
sue specimen to enable visual confirmation of soft-
ware performance. Ex vivo chicken tissue delineation 
was performed using a PLS-DA model to delineate 
fatty tissue from muscle tissue (100% cross-validated 
accuracy) (Supplementary Figure 6). Each of these 
features is intended to maximise robustness of our sys-
tem to different clinical settings and maintain clinician 
diagnostic control. 
To quantify the accuracy of our fluorescence-guided 
Raman spectroscopic system we delineated fatty 
chicken tissue from surrounding muscle tissue, ena-
bling comparison with ground truth visual margin de-
lineation (Supplementary Figure 7). Using our previ-
ously developed PLS-DA model (Supplementary Fig-
ure 5), we evaluated the margin delineation accuracy 
of our fluorescence-guided Raman spectroscopic 
system for three ex vivo chicken tissue specimens. De-
lineated areas closely resembled the ground truth ar-
eas in each case, as determined via manual image seg-
mentation (Supplementary Figure 7). Balancing true 
positive delineated area with false negative and false 
positive delineated areas, the best results were ob-
tained using a safety margin of 10 pixels for this par-
ticular setup, with a mean delineated true positive area 
of 86.5%, false negative of 13.5%, and false positive 
of 21.7% (Supplementary Figure 8). 
White Light-Guided Spectroscopic Margin Deline-
ation In Vivo 
We next investigated the feasibility of in vivo spectro-
scopic margin delineation in a nu/nu mouse SW122 
colorectal cancer xenograft tumour model (Figure 4). 
In vivo Raman spectra (n = 320) from SW122 xeno-
graft tumours and control flanks of two mice were col-
lected across multiple timepoints and used to develop 
a PLS-DA model with a cross-validated accuracy of 
96.5% (Figure 4d, Supplementary Figure 9). Applying 
our fluorescence-guided Raman spectroscopic system 
together with this PLS-DA model enabled real-time 
spectroscopic margin delineation of the SW122 tu-
mour tissue from the surrounding healthy tissue. Cru-
cially this process, in which each spectral acquisition 
takes ~2 seconds, can be performed in as little as 1 to 
2 minutes depending on the complexity of tumour ge-
ometry. While margin delineation accuracy in this 
case is much harder to calculate than for an ex vivo 
model due to the difficulties in obtaining ground truth 
data, this result points to the clinical potential of our 
fluorescence-guided Raman spectroscopic system for 
aiding tumour resection procedures in intraoperative 
settings. However, while promising, it should be noted 
that for such clinical applications, margin delineation 
accuracy is dependent on both the probe tracking ac-
curacy and the accuracy of the diagnostic model itself, 
e.g. the PLS-DA model applied here.  
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Figure 4 | White Light-Guided Spectroscopic Margin Delineation In Vivo. (a-b) Screenshots from the fluorescence-guided 
Raman spectroscopic system GUI during spatial spectroscopic diagnosis of (a) an SW122 colorectal xenograft tumour in 
a nu/nu mouse and (b) with AR Raman margin delineation overlay. (c) Mean Raman spectra of control tissue and SW122 
tumours (N = 2, n = 80) used for PLS-DA. (d) PLS-DA latent variable 1 and 2 (LV1 and LV2) scores for control tissue and 
SW122 tumours. 
 
Fluorescence-Guided Spectroscopic Margin Delin-
eation Ex Vivo 
While the in vivo and ex vivo margin delineation re-
sults achieved with our system under white light guid-
ance enabled the precise delineation of tumour mar-
gins, they do not address the first essential component 
for successful tumour resection – the initial detection 
and identification of suspicious lesions. Indeed, the 
macroscopic similarity between cancerous and 
healthy tissues is a key driver behind high post-surgi-
cal positive margin rates for many cancers. Therefore, 
to extend our system for comprehensive tumour resec-
tion assistance, we implemented fluorescence guid-
ance for our Raman spectroscopic margin delineation.  
After examining a range of fluorescent compounds 
currently employed for clinical and pre-clinical fluo-
rescence-guidance applications, we selected the pho-
tosensitiser compound protoporphyrin IX (PPIX). As 
we have previously demonstrated45, PPIX displays a 
low fluorescence background at clinically relevant 
concentrations under 785 nm Raman excitation (as 
typically applied in clinical Raman diagnostics) and is 
currently approved in the US and Europe for fluores-
cence-guided resection of high-grade gliomas12,46–48. 
In order to quantifiably demonstrate the benefit of flu-
orescence-guided Raman spectroscopic margin delin-
eation, we developed a series of tissue-mimicking flu-
orescent optical phantoms containing cellular and se-
rum components as well as varying PPIX concentra-
tions (Supplementary Figure 10). Raman spectro-
scopic characterisation demonstrated small differ-
ences in background fluorescent intensity between the 
0 µM, 2 µM, and 4 µM PPIX optical tissue phantoms 
with no obvious loss of Raman spectroscopic infor-
mation, while the 20 µM optical tissue phantom 
demonstrated considerable fluorescence background 
and was readily distinguished from the remaining op-
tical tissue phantoms via principal component analysis 
(PCA). Importantly, work quantifying the PPIX levels 
present in grade IV gliomas following the application 
of the PPIX precursor, 5-ALA, for fluorescence-
guided surgery has indicated a mean concentration of 
5.8 µM49 and we have previously demonstrated the 
possibility of performing Raman spectroscopic diag-
nosis in vivo on PPIX-containing tissues45. 
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We next developed a PLS-DA model to discriminate 
chicken muscle tissue from a non-fluorescent (0 µM 
PPIX) optical tissue phantom (100% cross-validated 
accuracy). We then applied this PLS-DA model for 
fluorescence-guided Raman margin delineation of 
both fluorescent and non-fluorescent optical tissue 
phantoms (Supplementary Figure 11). We were thus 
able to both detect fluorescent optical tissue phantoms 
within chicken tissue via fluorescence imaging and 
perform margin delineation via Raman spectroscopy 
(Figure 5). Although Raman spectral discrimination 
of the optical tissue phantoms and chicken tissue is 
trivial due to the significant spectral differences be-
tween the two materials, this experimental setup ena-
bled a quantitative comparison of the margin delinea-
tion accuracy of our fluorescence-guided Raman spec-
troscopic system and fluorescence imaging alone for 
a series of 0 µM, 2 µM, and 4 µM PPIX optical tissue 
phantoms (Supplementary Figure 12). While Raman 
spectroscopic margin delineation accuracy remained 
constant across the three PPIX concentrations, fluo-
rescence imaging margin delineation was much more 
dependent on the PPIX concentration, with fluores-
cence imaging unable to delineate the non-fluorescent 
optical tissue phantom (0 µM PPIX) (Supplementary 
Figure 13). When excluding the 0 µM PPIX optical 
tissue phantom data results, our fluorescence-guided 
Raman spectroscopic system performs as well as flu-
orescence imaging alone, with no statistically signifi-
cant difference in the true positive, false negative, or 
false positive areas delineated by the two techniques 
(Student’s t-test, n = 6) (Supplementary Figure 13c). 
However, our fluorescence-guided Raman spectro-
scopic system significantly outperformed fluores-
cence imaging alone for the 0 µM PPIX optical tissue 
phantom, with important implications for clinical ap-
plications to non-fluorescing tumour regions.
 
 
Figure 5 | Fluorescence-Guided Spectroscopic Margin Delineation Ex Vivo. (a-c) Screenshots of the fluorescence-guided 
Raman spectroscopic system during diagnosis and margin delineation of a 4 μM PPIX optical tissue phantom inserted into 
ex vivo chicken muscle tissue, (a) white light image, (b) fluorescence image, (c) AR overlay of Raman margin delineation 
onto white light image. 
 
Next, to better assess the potential of our fluorescence-
guided Raman spectroscopic system for tumour mar-
gin delineation, we created a composite optical tissue 
phantom with regions of varied fluorescence intensity 
(PPIX concentration) (Figure 6). Studies of FGS for 
high-grade gliomas have documented varying fluores-
cence intensity across tumours, particularly in ne-
crotic cores, regions of occluded tissue, and, most im-
portantly, at the tumour margins12,50. Here, margin de-
lineation by our fluorescence-guided Raman 
spectroscopic system vastly outperformed fluores-
cence imaging alone (87% true positive diagnostic 
area with safety margin of 10 pixels vs 26 % for fluo-
rescence imaging), with our system detecting the op-
tical tissue phantom independent of PPIX concentra-
tion. In contrast, fluorescence imaging was only able 
to detect the 4 µM PPIX region, due to the occlusion 
of the 2 µM PPIX region under a thin layer (~ 1 mm) 
of 0 µM PPIX optical tissue phantom.  
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Figure 6 | Tumour Mimicking Fluorescent Optical Tissue Phantom Margin Delineation Accuracy Evaluation. (a) Photo-
graph of the tumour mimicking fluorescent optical tissue phantom with regions of varying PPIX concentration. (b) Pho-
tograph of the tumour mimicking fluorescent optical tissue phantom with overlaid map of PPIX concentration regions. 
(c) Margin delineation accuracy for the tumour mimicking fluorescent optical tissue phantom via fluorescence-guided 
Raman spectroscopic margin delineation with safety margins of 0, 10, and 20 pixels, and via fluorescence imaging.  (d) 
Margin delineation of tumour mimicking optical tissue phantom using fluorescence-guided Raman spectroscopic margin 
delineation (with safety margins of 0, 10, and 20 pixels) and fluorescence imaging. (e) Corresponding true positive, false 
negative, and false positive areas for fluorescence-guided Raman spectroscopic margin delineation (with safety margins 
of 0, 10, and 20 pixels) and fluorescence imaging. 
 
This result thus demonstrates the complementarity of 
fluorescence imaging with Raman spectroscopic diag-
nostics, whereby fluorescence imaging enables rapid 
identification of fluorescence positive regions fol-
lowed by spatial spectroscopic diagnosis for accurate 
margin delineation independent of variation in fluo-
rescence intensity. As such, by developing diagnostic 
models that combine both fluorescence imaging infor-
mation and Raman spectroscopic information the two 
modalities could yield more accurate margin delinea-
tion in combination than either modality would 
achieve in isolation. However, an important caveat to 
note is that margin delineation accuracy via our fluo-
rescence-guided Raman spectroscopic system is de-
pendent on both the probe tracking accuracy and the 
accuracy of the underlying diagnostic model for spec-
troscopic discrimination between tumour and healthy 
tissue. Given the significant spectral differences be-
tween the optical tissue phantoms and the chicken tis-
sue used for these experiments, the results presented 
here reflect an idealised case where the underlying di-
agnostic model has a 100% discrimination accuracy.   
Discussion 
Successful surgical treatment of tumours is highly de-
pendent on the extent of tumour resection51,52. Despite 
this, post-surgical positive margin rates remain as high 
as 15-60% for a host of cancers due to both a lack of 
visual cues for the discrimination of healthy and can-
cerous tissues as well as the need to balance maximal 
tumour resection with healthy tissue preservation53. 
Though many technologies, such as intraoperative flu-
orescence imaging and spectroscopic diagnostics, 
have been developed towards improving tumour re-
section accuracy, no single system has adequately en-
abled both rapid tumour identification and accurate 
margin delineation54. The fluorescence-guided Raman 
spectroscopic system we report here is thus designed 
to enable both, without the introduction of complex, 
bulky, or expensive additional hardware into the oper-
ating theatre.  
High information content optical spectroscopies such 
as Raman spectroscopies have long held promise for 
tumour margin delineation. However, the long 
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acquisition times required have thus far restricted 
spectroscopy systems to point-based applications such 
that they cannot provide clinicians with a visual de-
marcation of a tumour boundary4,31,55. In contrast, flu-
orescence imaging offers visuals of a tumour’s extent, 
though this has typically been limited to high-grade 
tumours that generate sufficient contrast56. Im-
portantly, the performance of fluorescence imaging at 
tumour margins is typically low, impacting the ability 
to achieve accurate margin delineation47. 
Our fluorescence-guided Raman spectroscopic system 
is designed to bridge the gap between the high infor-
mation content of spectroscopy and the visual-spatial 
information provided by white light/fluorescence im-
aging. Through tracking the pose of a spectroscopic 
probe during spectral acquisitions, our system enables 
an AR display of the surgical FOV, overlaying spa-
tially co-registered spectroscopic diagnoses onto 
white light/fluorescence video image input for margin 
delineation. This combination of spatial and spectro-
scopic data thereby represents the first demonstration 
of rapid and accurate spectroscopic tumour margin de-
lineation for both ex vivo and in vivo settings.  
While our approach to tumour margin delineation has 
potential, several limitations will need to be overcome 
in order to enable successful clinical application. 
Firstly, performance should be enhanced to enable 
real-time operation. While much of this enhancement 
could be achieved through improved code parallelisa-
tion and computing hardware, this is also likely to re-
quire the use of a more sensitive Raman spectrometer 
in order to reduce signal acquisition times. Secondly, 
while the system currently provides a 2D AR overlay 
of spectroscopic and visual information, robust clini-
cal application will likely necessitate extension to 3D 
through the use of multiple cameras for stereovi-
sion57,58. This would enable improved depth percep-
tion for both probe tracking and margin delineation 
that could better represent complex tumours contours 
in vivo. Finally, for fluorescence-guided approaches, 
care will need to be taken to develop diagnostic mod-
els that include data from tumours with varying fluo-
rescence intensities in order to maximise perfor-
mance59. While we have demonstrated fluorescence-
guided Raman spectroscopy here using only optical 
tissue phantoms, we have previously reported on the 
feasibility Raman spectroscopic diagnosis of PPIX-
containing tissues in vivo and ex vivo45. Combined, 
these developments would likely prepare our proto-
type system for more comprehensive preclinical and 
clinical testing to evaluate its benefits for tumour re-
section surgeries. 
In conclusion, the combination of Raman spectro-
scopic diagnosis with fluorescence imaging and com-
puter vision probe tracking thus opens exciting oppor-
tunities for clinical tumour resection guidance. Given 
the improved cancer detection sensitivity spectro-
scopic methods have consistently shown relative to 
white light/fluorescence imaging modalities, our fluo-
rescence-guided Raman spectroscopic system will 
likely enable more accurate tumour margin delinea-
tion and could lead to improved rates of complete re-
section and thus better patient outcomes.  
 
Materials and Methods 
Fluorescence-Guided Raman Spectroscopic Sys-
tem 
The fluorescence-guided Raman spectroscopic system 
consisted of seven key components; a Raman spectro-
scopic probe with a 2.1 mm diameter (EmVision), a 
spectrograph (QEPro, OceanOptics), a Raman spec-
troscopy laser source (785 nm, 600 mW, B&W Tek), 
a 405 nm LED light source (600 mW, Thorlabs), an 8 
megapixel iSight camera (Apple) with a 500 nm 
longpass filter (Edmund Optics), and a computer 
(Lenovo Thinkpad T460, Intel Core i5-6200U CPU). 
System control software was developed in the 
MATLAB 2017B environment, using the MATLAB 
graphical user interface development environment 
(GUIDE), and the MATLAB image processing and 
computer vision toolboxes. 
Fluorescence-Guided Raman Spectroscopic Sys-
tem Characterisation 
Probe tracking accuracy was calculated using a video 
of probe movement in an ex vivo margin delineation 
setting. Computed coordinate locations for each of the 
fiducial markers and the probe tip were compared to 
ground truth coordinates, generated as the mean (n = 
3) user-identified coordinates for each video frame. 
Mean computation time (n = 3) was determined using 
the in-built MATLAB functions tic and toc for the 
core algorithm processing loop during a typical ex 
vivo margin delineation procedure.  
Ethics Statements 
Human samples used in this research project were ob-
tained from the Imperial College Healthcare Tissue 
Bank (ICHTB). ICHTB is supported by the National 
Institute for Health Research (NIHR) Biomedical Re-
search Centre based at Imperial College Healthcare 
NHS Trust and Imperial College London. ICHTB is 
approved by Wales REC3 to release human material 
for research (17/WA/0161), and the samples for this 
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project (R19022) were issued from the ICHTB Col-
lection. 
All animal studies were approved by the University 
College London Biological Services Ethical Review 
Committee and licensed under the UK Home Office 
regulations and the Guidance for the Operation of An-
imals (Scientific Procedures) Act 1986 (Home Office, 
London, United Kingdom) and United Kingdom Co-
ordinating Committee on Cancer Research Guidelines 
for the Welfare and Use of Animals in Cancer Re-
search60. 
Ex Vivo Diagnostic Model Development 
Using the fluorescence-guided Raman spectroscopic 
system, 25-30 Raman spectra were collected from raw 
ex vivo chicken muscle tissue, raw ex vivo chicken fat 
tissue, and the 0 µM, 2 µM, 4 µM, and 20 µM PPIX 
optical tissue phantoms. Fresh chicken tissue was ob-
tained from a local butcher on the day of experiments. 
Spectral processing was performed in MATLAB. 
Spectra were cropped, background subtracted (Whit-
taker filter, λ = 100,000), normalised to the area under 
the curve, and filtered (Savitzky-Golay, 1st order, 
frame width = 7) before different PLS-DA classifica-
tion models were developed with  Venetian blinds 
cross validation using PLS Toolbox (Eigenvector Re-
search) within the MATLAB environment. 
Ex Vivo Spectroscopic Margin Delineation 
Ex vivo fluorescence-guided Raman spectroscopic 
margin delineation was performed using the fluores-
cence-guided Raman spectroscopic system with a 785 
nm laser at 100 mW power output and a 1 second in-
tegration time with a previously developed PLS-DA 
model applied prospectively. 
Histology 
10 µm cryosections of human tissue biopsy samples 
were obtained following water embedding and freez-
ing using a Bright OTF cryostat. Cryosections were 
subsequently formalin fixed and stained with haema-
toxylin and eosin (H&E) in triplicate for each sample. 
Histology sample preparation and staining was per-
formed with the assistance of Lorraine Lawrence at 
Imperial College London’s Research Histology Facil-
ity within the Facility for Imaging by Light Micros-
copy (FILM). Imaging of stained sections was per-
formed using a Zeiss Axio Observer widefield in-
verted microscope with a 20x objective. 
Ex Vivo Margin Delineation Accuracy Characteri-
sation 
Ex vivo fluorescence-guided Raman spectroscopic 
margin delineation was performed on 3 raw chicken 
tissue specimens using the fluorescence-guided Ra-
man spectroscopic system with a 785 nm laser at 100 
mW power output and a 1 second integration time and 
a previously developed PLS-DA model applied pro-
spectively. For each specimen, between 22-26 spectral 
acquisitions were obtained and used to delineate the 
chicken fat tissue. Algorithm-delineated areas of 
chicken fat tissue, with safety margin sizes of 0, 10, 
and 20 pixels, were compared to the ground truth area 
and the size of true positive, false negative, and false 
positive regions determined. 
In Vivo Spectroscopic Margin Delineation 
Two female nu/nu mice (12 weeks old, 25-30g) were 
subcutaneously injected with 1x106 cells from a hu-
man colorectal carcinoma cell line, SW122, on their 
right flank. Using the fluorescence-guided Raman 
spectroscopic system, 80 Raman spectra were col-
lected from control mouse tissue in vivo and 80 spec-
tra from the SW122 xenograft tumours in vivo at 12 
days after implantation. Spectra were cropped, back-
ground subtracted (Whittaker filter, λ = 100,000), nor-
malised, and filtered (Savitzky-Golay, 1st order, frame 
width = 7) before a PLS-DA classification model of 
the spectra was developed with a Venetian blinds 
cross validation using PLS Toolbox (Eigenvector Re-
search) within the MATLAB environment. In vivo flu-
orescence-guided Raman spectroscopic margin delin-
eation of the SW122 xenograft tumours was then per-
formed using the fluorescence-guided Raman spectro-
scopic system with a 785 nm laser at 100 mW power 
output and a 1 second integration time using the pre-
viously developed PLS-DA model applied prospec-
tively. 
Cell Culture and Preparation for Optical Tissue 
Phantoms 
MDA-MB-231 cells (ATCC) for optical tissue phan-
toms were grown at 37 °C and 5% CO2 in high glucose 
(4.5 g/L) DMEM GlutaMax (Life Technologies) sup-
plemented with 10% (v/v) fetal bovine serum (FBS), 
1x penicillin-streptomycin, 1x non-essential amino 
acids, and 20 mM pH 7.3 HEPES buffer solution. The 
cell line was authenticated using STR profiling. Prior 
to inclusion in optical tissue phantoms, cells were 
trypsinised, spun down at 300 x g for 5 minutes, 
washed, and then fixed in 4% (v/v) PFA in PBS for 20 
minutes.  
Optical Tissue Phantom Construction 
Optical tissue phantoms that mimic tissue absorption 
and scattering were prepared using an adaptation of a 
previously established protocol61, by combining aga-
rose (Sigma-Aldrich), water, PBS (ThermoFisher), 
foetal bovine serum (FBS) (ThermoFisher), 
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homemade intralipid, and human haemoglobin. 
Homemade intralipid was made by forming a solution 
of 20% (v/v) sunflower oil and 1% DSPC (Avanti Po-
lar Lipids) in water. Briefly, 200 mg of agarose was 
dissolved in a 10 mL 1:1 solution of H2O:PBS and 
heated at 100 °C under constant stirring until a trans-
parent solution was formed. Solution was then al-
lowed to cool slowly to 50 °C. Once the solution 
reached 50 °C, 2.6 mL FBS, 200 μL of homemade in-
tralipid solution, 200 μL of human haemoglobin, and 
1 mL of 20 x 106 fixed MDA-MB-231 cells/mL were 
added and stirred through the solution. For fluores-
cence-guided applications, varying amounts of 500 
µM PPIX (Sigma-Aldrich) was also added to create 2 
µM, 4 µM, and 20 µM PPIX fluorescent optical tissue 
phantoms. The solution was then poured into a mould 
(e.g. cavity cut out of chicken tissue), as required, and 
allowed to cool to room temperature to set before use. 
Ex Vivo Fluorescence-Guided Margin Delineation 
Accuracy Characterisation 
Ex vivo fluorescence-guided Raman spectroscopic 
margin delineation was performed on raw chicken tis-
sue specimens with 0, 2, or 4 μM PPIX optical tissue 
phantom inserts using the fluorescence-guided Raman 
spectroscopic system with a 785 nm laser at 100 mW 
and a 1 second integration time and a previously de-
veloped PLS-DA model applied prospectively. For 
each specimen, between 10-30 spectral acquisitions 
were obtained and used to delineate the fluorescent 
optical tissue phantoms. Algorithm-delineated areas 
of fluorescent optical tissue phantom, with safety mar-
gin sizes of 0, 10, and 20 pixels, were compared to the 
ground truth area and the size of true positive, false 
negative, and false positive regions determined. 
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Supplementary Information 
 
Supplementary Figure 1 | HSV Image Segmentation for Coloured Marker-Based Spectroscopic Probe Tracking. (a-d) 
Image processing for coloured marker-based tracking takes (a) an input image frame and converts it from an RGB image 
to (b) an HSV image before (c) HSV-based image segmentation for identification and isolation of the coloured fiducial 
markers, which (d) is then combined with a priori knowledge of the probe geometry to calculate the pose of the spectro-
scopic probe and the location of the probe tip (black circle). 
 
 
Supplementary Figure 2 | Coloured Marker-Based Tracking of Spectroscopic Probe. (a-d) Sequential coloured marker-
based tracking video frames of the spectroscopic probe during a video sequence, with identified fiducial markers and 
probe tip, demonstrating robust tracking performance following partial occlusion of the spectroscopic probe.  
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Supplementary Figure 3 | Raman Spectroscopic PLS-DA Model of Ex Vivo Human Biopsy Specimens. (a) Mean Raman 
spectra of cancerous, normal (non-fat), and fatty (normal) tissues (N = 3-4 tissues, n ≥ 20 spectra). (b) PLS-DA latent 
variable 1 and 2 (LV1 and LV2) scores for cancerous, normal (non-fat), and fatty (normal) tissues, where PLS-DA latent 
variables represent spectral features of descending importance that best enable separation of the different tissue classes. 
(c) PLS-DA latent variable 1. (d) PLS-DA latent variable 2. (e) PLS-DA latent variable 3. 
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Supplementary Figure 4 | Fluorescence-Guided Raman Spectroscopic System Characterisation. (a) Video frame of mock 
Raman spectroscopic margin delineation video sequence of fresh chicken tissue used for characterisation of probe track-
ing error with overlaid ground truth and algorithm-determined probe-tip motion for entire video sequence. (b) Analysis 
of the processing time for the core spectroscopic margin delineation algorithm during (i) baseline loop iteration with 0.1 
second integration time (prior to spectroscopic diagnostic acquisitions), (ii) initial spectroscopic diagnostic acquisition 
with 1 second integration time, (iii) subsequent spectroscopic diagnostic acquisitions with 1 second integration time, and 
(iv) baseline loop iterations with 0.1 second integration time (between spectroscopic diagnostic acquisitions) (n = 3). (c-
d) Tracking error for probe tip and fiducial markers in (c) X and (d) Y for the mock spectroscopic margin delineation video 
sequence. 
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Supplementary Figure 5 | Fluorescence-Guided Raman Spectroscopic System Features. a-c, Video frames from the flu-
orescence-guided Raman spectroscopic system showing the delineated region of chicken fat tissue with safety margins 
value of (a) 0, (b) 10, and (c) 20 pixels. (d-f) Sequential video frames from the fluorescence-guided Raman spectroscopic 
system indicating iterative suggested measurement locations (yellow squares) dependent on the spatial distribution of 
existing positive diagnostic acquisitions. (g-i) Video frames from the fluorescence-guided Raman spectroscopic system 
showing the delineated region of chicken fat tissue with diagnostic thresholds of (g) 0%, (h) 85%, and (i) 100% where 
green squares indicate locations of negative (non-cancerous) acquisitions and red squares indicate positive (cancerous) 
acquisitions. (j-k) Video frames from the fluorescence-guided Raman spectroscopic system showing the resulting AR dis-
play of spatial spectroscopic diagnostic coordinates when video stabilisation is (j) enabled and (k) disabled. 
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Supplementary Figure 6 | Raman Spectroscopic PLS-DA Model of Ex Vivo Chicken Tissue. (a) Video frame from the 
fluorescence-guided Raman spectroscopic system showing chicken muscle and chicken fat tissue. (b) Mean Raman spec-
tra of chicken muscle tissue and chicken fat tissue (n = 25). (c) PLS-DA latent variable 1 (LV1) scores for chicken muscle 
tissue and chicken fat tissue Raman spectra. (d) PLS-DA latent variable 1.  
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Supplementary Figure 7 | White Light-Guided Spectroscopic Margin Delineation Ex Vivo Accuracy Evaluation. (a,c,e) 
Video frames from our fluorescence-guided Raman spectroscopic system showing the delineated margin of chicken fat 
tissue following 22-26 diagnostic spectral acquisitions with safety margin sizes of 0, 10, and 20 pixels for (a) specimen 1, 
(c) specimen 2, and (e) specimen 3. (b,d,f) Corresponding margin delineation accuracies indicating true positive (green), 
false negative (red), and false positive (yellow) diagnostic regions for (b) specimen 1, (d) specimen 2, and (f) specimen 3.  
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Supplementary Figure 8 | White Light-Guided Spectroscopic Margin Delineation Ex Vivo Accuracy Quantification. Mean 
normalised true positive, false negative, and false positive margin delineated areas for the ex vivo chicken tissue speci-
mens.  
 
 
Supplementary Figure 9 | Raman Spectroscopic PLS-DA Model Latent Variables for In Vivo SW122 Xenograft Mouse 
Tumour Model.  (a) PLS-DA latent variable 1. (b) PLS-DA latent variable 2. 
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Supplementary Figure 10 | Fluorescence Imaging and Raman Spectroscopy of PPIX Optical Tissue Phantoms in Ex Vivo 
Chicken Tissue. (a) Photograph of 0 µM, 2 µM, 4 µM, and 20 µM PPIX optical tissue phantoms inserted into chicken 
muscle tissue. (b-c) Fluorescence imaging of 0 µM, 2 µM, 4 µM, and 20 µM PPIX optical tissue phantoms in ex vivo chicken 
tissue. (d) Raw and (e) processed Raman spectra of the PPIX optical tissue phantoms and ex vivo chicken muscle tissue (n 
= 30). (f) PCA of the PPIX optical tissue phantoms and ex vivo chicken tissue Raman spectra. 
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Supplementary Figure 11 | Raman Spectroscopic PLS-DA Model of Ex Vivo Chicken Tissue and Optical Tissue Phantom. 
(a) Photograph of the 0 µM PPIX optical tissue phantom inserted into chicken tissue used to generate the PLS-DA model. 
(b) Mean Raman spectra of chicken tissue and optical tissue phantom (n = 30). (c) PLS-DA  latent variable 1 (LV1) scores 
for the chicken tissue and the optical tissue phantom Raman spectra. (d) PLS-DA latent variable 1.  
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Supplementary Figure 12 | Fluorescence-Guided Spectroscopic Margin Delineation Ex Vivo Accuracy Evaluation of PPIX 
Optical Tissue Phantoms. (a,c,e) Exemplar margin delineation of (a) 4 μM PPIX, (c) 2 μM PPIX, and (e) 0 μM PPIX optical 
tissue phantoms using fluorescence-guided Raman spectroscopic margin delineation (with safety margins of 0, 10, and 
20 pixels) and fluorescence imaging. (b,d,f) Corresponding true positive, false negative, and false positive areas for fluo-
rescence-guided Raman spectroscopic margin delineation (with safety margins of 0, 10, and 20 pixels) and fluorescence 
imaging. 
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Supplementary Figure 13 | Mean Fluorescence-Guided Spectroscopic Margin Delineation Ex Vivo Accuracy. (a-b) Mean 
phantom margin delineation accuracy for the 0 μM, 2 μM, and 4 μM PPIX optical tissue phantoms (n = 3) using (a) fluo-
rescence-guided Raman spectroscopic margin delineation and (b) fluorescence imaging. (c) Comparison of the mean 
margin delineation accuracy of fluorescence-guided Raman spectroscopic margin delineation and fluorescence imaging 
across the fluorescent optical tissue phantoms (2 μM and 4 μM PPIX). 
 
 
Supplementary Video 1 | White Light-Guided Spectroscopic Margin Delineation Ex Vivo. Video of white-light spectro-
scopic margin delineation of a human squamous cell carcinoma biopsy specimen. 
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Supplementary Video 2 | Demonstration of Fluorescence-Guided Raman Spectroscopic Diagnostic System Features. 
Video demonstrating implemented features for the fluorescence-guided Raman spectroscopic diagnostic system. 
